However, the correlation of MYD88 L265P and CD79B Y196 mutations with the prognosis of patients with PCNSL treated with R‐MPV has not been investigated in a large‐scale cohort subjected to a unified treatment regimen. Here, MYD88 is linked to primary central nervous system lymphoma.